Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer.
Yifan FuJInxin TaoYani GuYueze LiuJiangdong QiuDan SuRuobing WangWenhao LuoTao LiuFeifan ZhangTaiping ZhangYupei ZhaoPublished in: NPJ precision oncology (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm characterized by a poor prognosis and limited therapeutic strategy. The PDAC tumor microenvironment presents a complex heterogeneity, where neutrophils emerge as the predominant constituents of the innate immune cell population. Leveraging the power of single-cell RNA-seq, spatial RNA-seq, and multi-omics approaches, we included both published datasets and our in-house patient cohorts, elucidating the inherent heterogeneity in the formation of neutrophil extracellular traps (NETs) and revealed the correlation between NETs and immune suppression. Meanwhile, we constructed a multi-omics prognostic model that suggested the patients exhibiting downregulated expression of NETs may have an unfavorable outcome. We also confirmed TLR2 as a potent prognosis factor and patients with low TLR2 expression had more effective T cells and an overall survival extension for 6 months. Targeting TLR2 might be a promising strategy to reverse immunosuppression and control tumor progression for an improved prognosis.
Keyphrases
- single cell
- rna seq
- poor prognosis
- immune response
- toll like receptor
- long non coding rna
- inflammatory response
- high throughput
- end stage renal disease
- nuclear factor
- ejection fraction
- chronic kidney disease
- wastewater treatment
- case report
- randomized controlled trial
- peritoneal dialysis
- low grade
- systematic review
- cancer therapy
- patient reported outcomes
- high grade
- drug delivery
- anti inflammatory